Questcor Pharmaceuticals, Inc.
) recently announced its plans to commence a pilot effort to
commercialize H.P. Acthar Gel for the treatment of
respiratory manifestations of symptomatic sarcoidosis, a rare
This indication is a part of the FDA-approved package insert
for Acthar. Questcor intends to hire and train
5-10 sales representatives this quarter focusing on
pulmonologists treating this rare respiratory disorder.
The reps will start promoting the product for this indication
from the fourth quarter of this year. Questcor is yet to decide
whether a full-fledged sales force will be dedicated for this
indication. This pilot effort will provide input regarding future
commercialization plans for this indication. This pilot effort is
similar to those made by Questcor for Acthar in fields such as
neurology, nephrology and rheumatology.
Acthar, an injectable drug, is the lead product at Questcor.
It is approved by the FDA for as many as 19 indications including
nephrotic syndrome, dermatomyositis, polymyositis, systemic lupus
erythematosus, rheumatoid arthritis, multiple sclerosis relapses
and infantile spasms. Currently, Acthar is being studied for
amyotrophic lateral sclerosis and diabetic nephropathy.
The company shipped 4,830 vials of Acthar during the first
quarter of 2013, up 17.5% year over year but down sequentially by
23.7%. In Apr 2013, Questcor made a record by shipping 2,550
vials of Acthar to its distributor in a single month. In the
first quarter, Acthar's new paid prescriptions were about 1,725 -
1,750, up 16% year over year.
Questcor carries a Zacks Rank #3 (Hold). Right now, companies
Lannett Company, Inc.
) look well positioned with a Zacks Rank #1 (Strong Buy).
JAZZ PHARMACEUT (JAZZ): Free Stock Analysis
LANNETT INC (LCI): Free Stock Analysis Report
QUESTCOR PHARMA (QCOR): Free Stock Analysis
SANTARUS INC (SNTS): Free Stock Analysis
To read this article on Zacks.com click here.